PDS Biotech Aligns With FDA On Phase 3 Trial In HPV16-Positive First-Line Recurrent Or Metastatic Head And Neck Cancer
Portfolio Pulse from Benzinga Newsdesk
PDS Biotechnology Corporation (NASDAQ:PDSB) has aligned with the FDA on the next steps for its Phase 3 VERSATILE-003 trial targeting HPV16-positive head and neck cancer. The trial is set to begin in Q4 2024. A conference call will be held today at 8:00 a.m. ET to discuss the details.
August 01, 2024 | 11:51 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
PDS Biotechnology Corporation has received FDA alignment for its Phase 3 VERSATILE-003 trial targeting HPV16-positive head and neck cancer, set to begin in Q4 2024. This regulatory progress is a significant milestone for the company.
The FDA alignment for the Phase 3 trial is a critical regulatory milestone for PDS Biotech, likely to boost investor confidence and positively impact the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100